Judith Hsia, MD

Publications

• Nurmohamed NS, van Rosendael AR, Danad I, Ngo-Metzger Q, Taub PR, Ray KK, Figtree G, Bonaca MP, Hsia J, Rodriguez F, Sandhu AT, Nieman K, Earls JP, Hoffmann U, Bax JJ, Min JK, Maron DJ, Bhatt DL. Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography. Eur Heart J. 2024 May 27;45(20):1783-1800. PubMed PMID: 38606889
• Canonico ME, Low Wang CC, Hsia J, Debus ES, Nehler MR, Patel MR, Anand SS, Ycas J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs R, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization. J Am Coll Cardiol. 2024 Aug 27;84(9):801-811. PubMed PMID: 39168566
• Morrison JT, Canonico ME, Anand SS, Patel MR, Debus ES, Nehler MR, Hess CN, Hsia J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. Circulation. 2024 May 7;149(19):1536-1539. PubMed PMID: 38709838
• Hess CN, Daffron A, Nehler MR, Morrison JT, Buchanan CE, Szarek M, Anderson VE, Cannon CP, Hsia J, Saseen JJ, Bonaca MP. Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2024 Jun 25;83(25):2658-2670. PubMed PMID: 38897676
• Hsia J, Spyropoulos AC, Piazza G, Weng S, Dunne MW, Lipardi C, Barnathan ES, Bonaca MP. Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials. Thromb Haemost. 2024 Jul;124(7):649-655. PubMed PMID: 37995748
• Hsia J, Shivappa N, Bakhai A, Bover J, Butler J, Ferraro PM, Fried L, Schneider MP, Tangri N, Winkelmayer WC, Bishop M, Chen H, Sundin AK, Bonaca MP. Design and cohort characteristics of TRACK, a prospective study of hyperkalaemia management decision-making. Clin Kidney J. 2024 Oct;17(10):sfae295. PubMed PMID: 39464260
• Bikdeli B, Krishnathasan D, Khairani CD, Bejjani A, Davies J, Porio N, Tristani A, Armero A, Assi AA, Nauffal V, Campia U, Almarzooq Z, Wei E, Ortiz-Rios MD, Zuluaga-Sánchez V, Achanta A, Jesudasen SJ, Tiu B, Merli GJ, Leiva O, Fanikos J, Grandone E, Sharma A, Rizzo S, Pfeferman MB, Morrison RB, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll B, Goldhaber SZ, Lan Z, Piazza G. Low absolute risk of thrombotic and cardiovascular events in outpatient pregnant women with COVID-19. Thromb Res. 2024 May;237:209-215. PubMed PMID: 38677791
• Naveh S, Rogers RK, Hess CN, Nehler MR, Hsia J, Bonaca MP. Multidisciplinary Management of Chronic Limb Threatening Ischemia. JACC Case Rep. 2024 Dec 4;29(23):102717. PubMed PMID: 39691331
• Low Wang CC, Chong T, Moore G, Echalier B, Haakonsen N, Carter JE Jr, Mathes D, Hsia J, Phan TT, Lim IJ, Freed BM. Results of the Phase 1 Open-Label Safety Study of Umbilical Cord Lining Mesenchymal Stromal/Stem Cells (Corlicyte(®)) to Heal Chronic Diabetic Foot Ulcers. Biomedicines. 2024 Jun 20;12(6). PubMed PMID: 38927582
• Gluckman TJ, Chiu ST, Rider D, Tseng PK, Mudd JO, Remick JD, Granowitz C, Carroll A, Sikirica S, Canonico ME, Hsia J, Bonaca MP. Relationship Between Left Ventricular Ejection Fraction and ICD-10 Codes Among Patients Hospitalized With Heart Failure. Clin Cardiol. 2024 Dec;47(12):e70055. PubMed PMID: 39686565
• Piazza G, Spyropoulos AC, Hsia J, Goldin M, Towner WJ, Go AS, Bull TM, Weng S, Lipardi C, Barnathan ES, Bonaca MP. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial. Circulation. 2023 Jun 20;147(25):1891-1901. PubMed PMID: 37154020
• Bikdeli B, Khairani CD, Krishnathasan D, Bejjani A, Armero A, Tristani A, Davies J, Porio N, Assi AA, Nauffal V, Campia U, Almarzooq Z, Wei E, Achanta A, Jesudasen SJ, Tiu BC, Merli GJ, Leiva O, Fanikos J, Sharma A, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll BJ, Lan Z, Goldhaber SZ, Piazza G. Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study. Thromb Res. 2023 Aug;228:94-104. PubMed PMID: 37302267
• Sauer AJ, Hsia J. Initiating Mineralocorticoid Antagonists for Longstanding Heart Failure With Reduced Ejection Fraction: Better Late Than Never?. J Am Coll Cardiol. 2023 Sep 12;82(11):1092-1095. PubMed PMID: 37642609
• Canonico ME, Piccolo R, Avvedimento M, Leone A, Esposito S, Franzone A, Giugliano G, Gargiulo G, Hess CN, Berkowitz SD, Hsia J, Cirillo P, Esposito G, Bonaca MP. Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. J Cardiovasc Dev Dis. 2023 Apr 10;10(4). PubMed PMID: 37103043
• Canonico ME, Hsia J, Hess CN, Bonaca MP. Sex differences in guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease. Vasc Med. 2023 Jun;28(3):233-235. PubMed PMID: 36847166
• Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH, Johri S, Pursley MS, Gupta R, Meehan PS, Franchi F, Effron MB, Marshall D, Graybill CA, Huebler SP, Keuer T, Bristow MR, Bonaca MP. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arterioscler Thromb Vasc Biol. 2023 Aug;43(8):1572-1582. PubMed PMID: 37381988
• Hsia J, Spyropoulos AC, Piazza G, Weng S, Dunne MW, Lipardi C, Barnathan ES, Bonaca MP. Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials. Thromb Haemost. 2023 Dec 21. [Epub ahead of print] PubMed PMID: 37995748
• Kondapalli L, Hsia J, Miller M, Flaig T, Bonaca MP. Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded Outcomes, JACC CardioOnc.2022;4:649–656
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Uptake of newer guideline-directed therapies in heart failure patients with diabetes or chronic kidney disease. JACC Heart Fail 2022; 10: 989-991 doi: 10.1016/j.jchf.2022.09.013
• Hsia J, Guthrie NC, Paul Lupinacci P et al. Randomized, controlled trial of a digital behavioral therapeutic application to improve glycemic control in adults with type 2 diabetes. Diab Care 2022;45:2976-2981
• Sesso HD, Manson JAE, Aragaki AK…Hsia J et al. Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. Am J Clin Nutr 2022;115:1490-1500
• Sesso HD, Rist PM, Aragaki AK ….Hsia J et al. Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. Am J Clin Nutr 2022;115:1501-10
• Canonico ME, Hsia J, Guthrie NL et al. Cognitive Behavioral Therapy Delivered Via Digital Mobile Application for the Treatment of Type 2 Diabetes: Rationale, Design and Baseline Characteristics of a Randomized, Controlled Trial. Clin Cardiol 2022; 45: 850-856. doi.org/10.1002/clc.23853
• Hess CN, Baumgartner I, Anand SS…Hsia J. Sex-Based Differences in Outcomes following Peripheral Artery Revascularization: Insights from VOYAGER PAD, JAHA 2022;11:e024655. doi: 10.1161/JAHA.121.02465
• Hess CN, Szarek M, Anand SS …Hsia J et al. Risk of Venous Thromboembolism and Effect of Rivaroxaban in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization, JAMA Network Open 2022; 5(6): e2215580. doi:10.1001/jamanetworkopen.2022.15580
• Szarek M, Hess C, Patel MR… Hsia J et al. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic PAD. JAHA 2022;11:e025504. doi: 10.1161/JAHA.122.025504
• Berkowitz S, Bauersachs RM, Szarek M…Hsia J et al. Prevention of Arterial And Venous Thrombotic Events In Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet Therapy Alone. J Thromb Haemost 2022;20:1193–1205. doi: 10.1111/jth.15673
• Hogan SE, Nehler MR, Anand S… Hsia J, Bonaca MP. Walking Impairment Following Surgical and Endovascular Revascularization: Insights from VOYAGER PAD. Vasc Med 2022; 27: 343-9. doi: 10.1177/1358863X221085606
• Hess CN, Capell WG, Bristow MR…Hsia J, Bonaca MP. Rationale and design for the study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 study. Am Heart J 2022; 246: 136-143. doi: 10.1016/j.ahj.2021.12.010
• Bonaca MP, Guthrie NL Lupinacci P…Hsia J. Randomized, Controlled Trial of Digital Nutritional Cognitive Behavioral Therapy in Patients with Type 2 Diabetes Mellitus: Primary Outcomes of the BT-001 Pivotal Trial at 180 Days. Presented AHA Scientific Sessions 2022
• King RW, Nehler MR, Manesh R. Patel MR … Hsia J et al. Risk Stratification for Amputation in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD. Circ 2022;146:A9928
• Hogan S, Patel MR, Debus ES… Hsia J et al. Unplanned Limb Revascularization with Rivaroxaban versus Placebo in Patients with Critical Limb Ischemia after Endovascular and Surgical Treatment: Insights from VOYAGER PAD. Circ 2022;146:A10889
• Khairani C, Bejjani A, Carroll B…Hsia JA et al. Diabetes is Associated With Increased Risk of Major Adverse Cardiovascular Events in Patients Covid-19: A Retrospective US Multicenter Cohort Study. Circ 2022;146:A15606
• Piazza G, Spyropoulos A, Hsia J et al. Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic events, Hospitalization and Death in Medically Ill Outpatients With COVID-19: Primary Results of the PREVENT-HD Randomized Clinical Trial. Presented AHA Scientific Sessions 2022
• Hsia J, Spyropoulos A, Piazza G et al. Rivaroxaban to Improve Clinical Outcomes in Outpatients with COVID-19: a meta-analysis of PREVENT-HD and the Bill and Melinda Gates Medical Research Institute trial. Circ 2022;146:A10258
• Canonico ME, Capell W, Anand SS…Hsia J et al. Causes of Death in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD. Circ 2022;146:A12197
• Buchanan CE, Szarek M, Eike Sebastian Debus ES … Hsia J et al. Lower May Not Be Better: Systolic Blood Pressure and Risk of Major Adverse Limb Events in Patients with Symptomatic Peripheral Artery Disease after Revascularization: Insights from VOYAGER PAD. Circ 2022;146:A10240
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) are underutilized in 2021-22 in patients with heart failure without diabetes. Circ 2022;146:A10477
• Hess CN, Nehler MR, Morrison JT, Buchanan C, Anderson VE, Cannon CP, Hsia J, Bonaca MP. Pragmatic Implementation Science in Peripheral Artery Disease: Design and Conduct of OPTIMIZE PAD-1, Vasc Med doi: 10.1177/1358863X221127748, p25
• Buchanan C, Hogan SE, King RW, Nehler MR, Hsia J, Bonaca MP. Exercise therapy for symptomatic peripheral artery disease following surgical and endovascular peripheral revascularization: could we do better? Vasc Med doi: 10.1177/1358863X221127748, p20
• Hsia J, Guthrie NL, Lupinacci P, Gubbi A, Denham D, Berman MA, Bonaca MP. Randomized, controlled trial of a digital therapeutic app providing nutritional cognitive behavioral therapy for the treatment of type 2 diabetes. Vasc Med doi: 10.1177/1358863X221127748, p14
• Anderson VE, Delva-Clark H, Capell W, Hogan SE, Rogers RK, Cannon C, Hsia J, Bonaca M. Effect of course length on total distance walked during monitored 6-minute walk test within a randomized clinical trial. Vasc Med doi: 10.1177/1358863X221127748, p17
• Canonico ME, Hsia J, Hess CN, Bonaca MP. Guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease (PAD). Vasc Med doi: 10.1177/1358863X221127748, p21
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) for heart failure are underutilized in 2021-2 in patients with chronic kidney disease, J Am Soc Nephrol 2022;33:217
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Newer guideline-directed medical therapies (GDMT) are underutilized in 2021 in patients with heart failure with or without diabetes. Diabetes 2022;71(Suppl_1):868-P doi: 10.2337/db22-868-P
• Hess CN, Nehler MR, Hsia JA et al. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN Phase 2b Randomized Trial. ATVB 2022;42 (Suppl 1):A113. Winner of the AHA Paul Dudley White International Scholar Award as the highest scoring abstract at Vascular Discovery 2022
• Svet M, Hsia J, Patel MR et al. Rivaroxaban Reduces Thrombotic Hospitalizations in Patients with Peripheral Artery Disease After Revascularization in those with and without chronic kidney disease. JACC 2022; 79: 9 Suppl 1739
• Heilman A, Bauersachs R, Anand S … Hsia J et al. Benefits of rivaroxaban after lower extremity revascularization for symptomatic peripheral artery disease are consistent with and without background statin therapy. JACC 2022; 79: 9 Suppl 1747
• Szarek M, Hess C, Patel MR…Hsia J et al. Total cardiovascular and limb events with ticagrelor and clopidogrel in patients with symptomatic PAD in the EUCLID trial. JACC 2022 79:9 Suppl 1744
• Hogan SE, Nehler MR, Anand S… Hsia J, Bonaca MP. Walking Impairment Following Surgical and Endovascular Revascularization: Insights from VOYAGER PAD. JACC 2022; 79: 9 Suppl 1774
• Canonico ME, Hsia J, Cannon CP, Bonaca MP. Sex differences in guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease. Vasc Med, in press